Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Apr;7(4):1023-9.
doi: 10.1002/j.1460-2075.1988.tb02909.x.

c-myc down-regulates class I HLA expression in human melanomas

Affiliations

c-myc down-regulates class I HLA expression in human melanomas

R Versteeg et al. EMBO J. 1988 Apr.

Abstract

Expression of class I HLA antigen has been shown to be reduced in a number of human tumours. Here we show that in a panel of 11 melanoma cell lines with variable class I HLA expression an inverse correlation exists between the mRNA levels of c-myc and class I HLA. This suggests that high expression of the c-myc oncogene might inhibit the class I HLA expression. To test this hypothesis a melanoma cell line with a low c-myc and high class I HLA mRNA expression was transfected with a c-myc expression vector. All clones expressing the transfected c-myc gene show reduced class I HLA mRNA and beta 2-microglobulin mRNA expression. Reduced class I HLA mRNA levels result in a lowered class I protein expression on the cell surface. Treatment with gamma-interferon fully restores the class I HLA and beta 2-microglobulin expression in these cells. This effect is preceded by a transient decrease of the c-myc mRNA level. These results show that the class I HLA expression is modulated by the level of c-myc expression, thus opening up the possibility that high expression of this oncogene influences the interaction of melanoma cells with the immune system.

PubMed Disclaimer

References

    1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
    1. Nature. 1983 Aug 18-24;304(5927):596-602 - PubMed
    1. Adv Immunol. 1979;27:51-177 - PubMed
    1. J Natl Cancer Inst. 1980 May;64(5):1029-40 - PubMed
    1. Methods Enzymol. 1980;65(1):826-39 - PubMed

Publication types